- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00810472
Functional Antigen Matching in Corneal Transplantation (FANCY)
October 24, 2016 updated by: Daniel Böhringer, University Hospital Freiburg
Clinical Trial to Investigate Superiority of HLA Matching in Comparison to Random Graft Assignment With Respect to the Endpoint 'Time to First Endothelial Graft Rejection' in Penetrating Keratoplasty.
Penetrating keratoplasty is one of the most commonly performed transplantation surgeries.
Graft rejection is a major complication.
HLA compatibility has already been demonstrated an effective prophylaxis in several retrospective investigations.
The purpose of the investigators randomized clinical trial is to demonstrate superiority of HLA matching in comparison to random graft assignment with respect to the endpoint 'time to first endothelial graft rejection' in penetrating keratoplasty.
The investigators will perform DNA-based allele resolution typing.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
650
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Baden-Württemberg
-
Freiburg, Baden-Württemberg, Germany, 79106
- University eye hospital Freiburg
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Predicted waiting time for a 4/6 match lower than 6 months.
Exclusion Criteria:
- Minority
- Legal incapacity
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: HLA Matching
HLA matching is exerted by selecting the donor with least-most additional HLA alleles.
We will predict the waiting time for such a donor in order to assess eligibility for the trial [8].
In addition, we will dynamically adopt the degree of matching that is aimed at depending on the predicted time interval and actual waiting time: the first donors not exerting more than 7 mismatches at the triplet-amino-acid-residue-level (HLAMatchmaker method [6]) is accepted if the patient is waiting less than half of his predicted waiting time.
The next available donor exerting a 2/6 match (or better) is assigned thereafter.
The next graft will be assigned, regardless of HLA matching after 6 months.
|
HLA matching is exerted by selecting the donor with least-most additional HLA alleles.
We will predict the waiting time for such a donor in order to assess eligibility for the trial [8].
In addition, we will dynamically adopt the degree of matching that is aimed at depending on the predicted time interval and actual waiting time: the first donors not exerting more than 7 mismatches at the triplet-amino-acid-residue-level (HLAMatchmaker method [6]) is accepted if the patient is waiting less than half of his predicted waiting time.
The next available donor exerting a 2/6 match (or better) is assigned thereafter.
The next graft will be assigned, regardless of HLA matching after 6 months.
Corneal transplantation.
|
PLACEBO_COMPARATOR: Random graft assignment
|
Corneal transplantation.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Time to first endothelial graft rejection.
Time Frame: Mostly within the first six months.
|
Mostly within the first six months.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Bohringer D, Spierings E, Enczmann J, Bohringer S, Sundmacher R, Goulmy E, Reinhard T. Matching of the minor histocompatibility antigen HLA-A1/H-Y may improve prognosis in corneal transplantation. Transplantation. 2006 Oct 27;82(8):1037-41. doi: 10.1097/01.tp.0000235908.54766.44.
- Reinhard T, Spelsberg H, Henke L, Kontopoulos T, Enczmann J, Wernet P, Berschick P, Sundmacher R, Bohringer D. Long-term results of allogeneic penetrating limbo-keratoplasty in total limbal stem cell deficiency. Ophthalmology. 2004 Apr;111(4):775-82. doi: 10.1016/j.ophtha.2003.07.013.
- Reinhard T, Bohringer D, Enczmann J, Kogler G, Mayweg S, Wernet P, Sundmacher R. Improvement of graft prognosis in penetrating normal-risk keratoplasty by HLA class I and II matching. Eye (Lond). 2004 Mar;18(3):269-77. doi: 10.1038/sj.eye.6700636.
- Bohringer D, Reinhard T, Duquesnoy RJ, Bohringer S, Enczmann J, Lange P, Claas F, Sundmacher R. Beneficial effect of matching at the HLA-A and -B amino-acid triplet level on rejection-free clear graft survival in penetrating keratoplasty. Transplantation. 2004 Feb 15;77(3):417-21. doi: 10.1097/01.TP.0000110415.10401.94.
- Reinhard T, Bohringer D, Enczmann J, Kogler G, Wernet P, Bohringer S, Sundmacher R. HLA class I/II matching and chronic endothelial cell loss in penetrating normal risk keratoplasty. Acta Ophthalmol Scand. 2004 Feb;82(1):13-8. doi: 10.1046/j.1600-0420.2003.00188.x.
- Bohringer D, Reinhard T, Enczmann J, Godehard E, Sundmacher R. Individual analysis of expected time on the waiting list for HLA-matched corneal grafts. Dev Ophthalmol. 2003;36:50-5. doi: 10.1159/000067648.
- Bohringer D, Grotejohann B, Ihorst G, Reinshagen H, Spierings E, Reinhard T. Rejection Prophylaxis in Corneal Transplant. Dtsch Arztebl Int. 2018 Apr 13;115(15):259-265. doi: 10.3238/arztebl.2018.0259.
- Bohringer D, Ihorst G, Grotejohann B, Maurer J, Spierings E, Reinhard T; FANCY study group. Functional antigen matching in corneal transplantation: matching for the HLA-A, -B and -DRB1 antigens (FANCY) - study protocol. BMC Ophthalmol. 2014 Dec 13;14:156. doi: 10.1186/1471-2415-14-156.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2009
Primary Completion (ACTUAL)
May 1, 2015
Study Completion (ACTUAL)
May 1, 2015
Study Registration Dates
First Submitted
December 17, 2008
First Submitted That Met QC Criteria
December 17, 2008
First Posted (ESTIMATE)
December 18, 2008
Study Record Updates
Last Update Posted (ESTIMATE)
October 25, 2016
Last Update Submitted That Met QC Criteria
October 24, 2016
Last Verified
October 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- FR-2008-FANCY
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Corneal Diseases
-
Keratoplasty Alliance InternationalRecruitingCorneal Disease | Corneal Transplant Failure | Endothelial Corneal Dystrophy | Corneal Transplant RejectionUnited States
-
Umeå UniversityGlaukos CorporationCompletedEye Diseases | Keratoconus | Corneal Disease | Corneal Crosslinking | Corneal Biomechanics | Corneal Densitometry | Scheimpflug PhotographySweden
-
Oregon Health and Science UniversityNational Eye Institute (NEI); National Institutes of Health (NIH)Completed
-
Umeå UniversityGlaukos CorporationActive, not recruitingEye Diseases | Keratoconus | Corneal Crosslinking | Corneal Densitometry | Scheimpflug Photography | Corneal DisorderSweden
-
University of California, IrvineWithdrawnCORNEAL OPACITY WITH POOR PROGNOSIS FOR CORNEAL TRANSPLANTUnited States
-
Cornea and Laser Eye InstituteRecruitingKeratoconus | Corneal Ectasia | Irregular Astigmatism | Aberration, Corneal Wavefront | Wavefront Aberration, Corneal | Pellucid Marginal Corneal Degeneration | KeratoglobusUnited States
-
Tianjin Eye HospitalRecruitingDeep Learning, Corneal Disease, ScreeningChina
-
Klinikum Chemnitz gGmbHTechnische Universität DresdenCompletedCorneal Ulcers | Corneal MeltingGermany
-
University Hospital, Strasbourg, FranceTerminatedKeratitis | Pterygium | Corneal Perforation | Corneal Opacity Corneal ThinningFrance
-
University of Texas Southwestern Medical CenterCompletedCorneal Edema Secondary to Corneal Endothelial DystrophyUnited States
Clinical Trials on HLA Matching
-
Ain Shams UniversityCompleted
-
Second Xiangya Hospital of Central South UniversityRecruiting
-
Ann & Robert H Lurie Children's Hospital of ChicagoCompleted
-
Fondazione Policlinico Universitario Agostino Gemelli...Completed
-
Baylor College of MedicineThe Methodist Hospital Research InstituteRecruitingViral InfectionUnited States
-
Piera BoschettoCompleted
-
State-Financed Health Facility "Samara Regional...INBIO, LLCRecruitingCerebral PalsyRussian Federation
-
Iwate Medical UniversityHuman Genome Center, Institute of Medical Science, University of TokyoCompletedRenal Cell Carcinoma
-
Shiga UniversityHuman Genome Center, Institute of Medical Science, University of TokyoCompletedNon-small Cell Lung CancerJapan
-
Memorial Sloan Kettering Cancer CenterM.D. Anderson Cancer Center; Mayo Clinic; Dana-Farber Cancer Institute; Duke University and other collaboratorsActive, not recruitingLeukemiaUnited States